{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.82","value":"-1.1"},{"groupId":"OG001","spread":"14.01","value":"-3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"196"}],"units":"Participants"}],"description":"The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received tislelizumab 200 mg administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.","id":"OG000","title":"Tislelizumab + Chemotherapy"},{"description":"Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.","id":"OG001","title":"Placebo + Chemotherapy"}],"paramType":"MEAN","populationDescription":"Participants in the ITT Analysis Set with EQ-5D-5L measurement at both Baseline and Cycle 6.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 6 (Week 15)","title":"Change From Baseline in European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS)","type":"SECONDARY","unitOfMeasure":"score on a scale"}